Department of Pharmacognosy
PhD: School of Pharmacy, University of Louisiana-USA (2017).
Master: Faculty of Pharmacy, Alexandria University-Egypt (2011).
B.SC: Faculty of Pharmacy, Alexandria University-Egypt (2007).
Career History and Professional Experience
Experienced Assistant Professor with a demonstrated history of working in the higher education industry. Skilled in natural products chemistry, with multidisciplinary research experience in molecular biology & computational drug discovery. Experience in using computational approaches for the goal of hit identification, establishing SARs, & hit to lead optimization. Strong research professional with a PhD focused in Pharmacognosy from The University of Louisiana.
2017-Present: Assistant Professor of Natural Products Chemistry, Faculty of Pharmacy, Alexandria University.
2013-2016: Teaching & Research Assistant, School of Pharmacy, University of Louisiana-USA.
2011-2013: Assistant Lecturer of Pharmacognosy, Faculty of Pharmacy, Alexandria University.
2007-2011: Demonstrator of Pharmacognosy, Faculty of Pharmacy, Alexandria University.
Natural Products Chemistry
Computational Drug Discovery
SARs & Semisynthetic Optimization
- Academic Positions
- Teaching Summary
- Journal Publications
- Conference Publications
- Funded Research Grants
- 2017-Present Assistant Professor of Natural Products Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- 2020-Present Visiting Assistant Professor of Natural Products Chemistry, Faculty of Pharmacy, Alamein International University (AIU), Alamein, Egypt.
- 2017-2019 Visiting Assistant Professor of Natural Products Chemistry, Faculty of Pharmacy, Pharos University in Alexandria (PUA), Alexandria, Egypt.
- 2017-2018 Visiting Assistant Professor of Natural Products Chemistry, Faculty of Pharmacy, Damanhour University, El-Behaira, Egypt.
- 2013-2016 Teaching & Research Assistant, School of Pharmacy, University of Louisiana-Monroe, Louisiana.
- 2011-2013 Lecturer of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- 2007-2011 Assistant Lecturer of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- Pharmacognosy I & II –Essential fundamentals of medicinal botanicals (2 Cr. Lec + 1 Cr. Lab).
- Phytochemistry I & II –Intensive background of the chemistry of natural products and their methods of screening, extraction, separation, and quantitative analysis (2 Cr. Lec + 1 Cr. Lab).
- Quality Control of Herbal Medicines – Principles of compendial qualitative and quantitative quality control methods used for the evaluation of herbal products, (2 Cr. Lec + 1 Cr. Lab).
- Fundamentals of Phytotherapy – Modern phytopharmacotherapy and clinical evidence base for the safety and efficacy of herbal products (2 Cr. Lec + 1 Cr. Tutorial).
- Applied Pharmacognosy – Intensive knowledge of different chromatographic techniques used in the analysis of phytopharmaceuticals and herbal preparations (2 Cr. Lec + 1 Cr. Lab).
- Natural Products Drug Discovery: Comprehensive information of several approaches involved in the natural products drug discovery process (2 Cr. Lec + 1 Cr. Tutorial).
- Computer-Aided Drug Discovery & Design: Tutorial and Lab Exercises: Medicinal Chemistry Research Problems. (1 Cr. tutorial + 2 Cr. Lab); 3-10 students per class).
- Pharmacy Integrated Lab Sequences: Chemical and spectral exercises on the chemistry of antibiotics with clinical relevance. (1 Cr. tutorial + 2 Cr. Lab; 20-30 students per class).
- Undergraduate Summer Research: Design experiments and work directly with students to conduct undergraduate research projects regarding natural products drug discovery. Throughout this summer research school, several undergraduate students have been trained to conduct research and present their data in student research symposiums.
1. D. Ghallab, M. Mohyeldin, E. Shawky, A. Metwally, and R. Ibrahim; Chemical profiling of Egyptian propolis and determination of its xanthine oxidase inhibitory properties using UPLC-MS/MS and chemometrics. LWT-Food Science and Technology, 2020. In press. IF: 4.006.
2. K. Abdelwahed, A. Siddique, M. Mohyeldin, M. Qusa, A. Goda, S. Singh, N. Ayoub, J. King, S. Jois, and K. El Sayed; Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor. Pharmacol. Res., 2020; 158: 104847. IF (2019): 5.574.
3. A. Siddique, H. Ebrahim, M. Mohyeldin, M. Qusa, Y. Batarseh, A. Fayyad, A. Tajmim, S. Nazzal, A. Kaddoumi, and K. El Sayed; Novel liquid-liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (-)-oleocanthal and its oral anti-breast cancer activity. PLoS One, 2019; 14: e0214798. IF: 2.766.
4. A. Siddique, H. Ebrahim, M. Akl, N. Ayoub, A. Goda, M. Mohyeldin, S. Nagumalli, W. Hananeh, Y. Liu, S. Meyer, and K. El Sayed; (-)-Oleocanthal combined with lapatinib treatment synergized against HER-2 positive breast cancer in vitro and in vivo. Nutrients, 2019; 11: 412-430. IF (2018): 4.171.
5. S. Souid, H. Elsayed, H. Ebrahim, M. Mohyeldin, A. Siddique, H. Karoui, K. El Sayed, and K. Essafi‐Benkhadir; 131‐Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal‐epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo. Mol. Carcinog, 2018; 57:1507-1524. IF (2018): 3.411.
6. S. Mohy El-Din and M. Mohyeldin; Component analysis and antifungal activity of the compounds extracted from four brown seaweeds with different solvents at different seasons. J. Ocean Univ. China, 2018; 17:1178-1188. IF (2018): 0.699.
7. A. Goda, A. Siddique, M. Mohyeldin, N. Ayoub, and K. El Sayed; The Maxi-K (BK) channel antagonist penitrem A as a novel breast cancer-targeted therapeutic. Mar. Drugs, 2018; 16: 157-177. IF (2018): 3.772.
8. A. Siddique, H. Ebrahim, M. Mohyeldin, S. Jois, and K. El Sayed; Abstract 2683: The olive-based oleocanthal as a dual HER2-MET inhibitor for the control of breast cancer recurrence. Cancer Res., 2018; 78 (13 Supplement): 2683-2683. IF (2018): 9.13.
9. H. Elsayed, H. Ebrahim, M. Mohyeldin, A. Kamal, M. Akl, E. Haggag, and K. El Sayed; Rutin as a novel c-Met inhibitory lead for the control of triple negative breast malignancies. Nutr. Cancer, 2017; 69: 1256-1271. IF (2017): 2.261.
10. M. Hailat, H. Ebrahim, M. Mohyeldin, A. Goda, A. Siddique, and K. El Sayed; The tobacco cembranoid (1S,2E,4S,7E,11E)-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitory lead for the control of breast malignancies. Bioorg. Med. Chem., 2017; 25: 3911-3921. IF (2018): 2.802.
11. N. Ayoub, A. Siddique, H. Ebrahim, M. Mohyeldin, and K. El Sayed; The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. Eur. J. Pharmacol., 2017; 810: 100-111. IF (2018): 3.17.
12. M. Mohyeldin, M. Akl, A. Siddique, H. Hassan, and K. El Sayed; The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR. Biochem. Pharmacol., 2017; 126: 51-68. IF (2018): 4.825.
13. A. Siddique, H.Y. Ebrahim, M. Akl, M. Mohyeldin, and K. El Sayed; Abstract 1077: Extra-virgin olive oil Met inhibitor oleocanthal-lapatinib: A novel synergistic combination for HER2-dependent breast malignancies. Cancer Res., 2017; 77 (13 Supplement):1077-1077. IF (2018): 9.13.
14. A. Elmaidomy†, M. Mohyeldin†, M. Ibrahim, H. Hassan, E. Amin, M. Rateb, M. Hetta, and K. El Sayed; Acylated iridoids and rhamnopyranoses from Premna odorata (Lamiaceae) as novel mesenchymal-epithelial transition factor receptor inhibitors for the control of breast cancer. Phytother. Res., 2017; 31: 1546–1556. † Both authors equally contributed. IF: 3
1. M. Mohyeldin, A. Goda and K. El Sayed; Discovery of the marine dibromotyrosines as a novel c-Met kinase inhibitory class for breast cancer control. Abstracts of the 2nd PUA International Conference ICMAPS, Alexandria, Egypt, 2020.
2. M. Abdelhakim, M. Soliman, A. Ibrahim, D. Abu el Magd, S. Mostafa, S. Salama, M. Soliman, Y. Shekeban, R. Awwad, O. Ellazdy, F. Oshayba, M. Makar, A. Alkashef and M. Mohyeldin; Computer-assisted discovery of novel natural product inhibitors of Brk tyrosine kinase for triple negative breast cancer control. International Conference on Pharmaceutical and Healthcare Sciences “PHS 2019”, Alexandria, Egypt, 2019.
3. A. Siddique, H. Ebrahim, M. Mohyeldin, N. Ayoub, S. Singh, S. Jois, and K. El Sayed; PO-406: The olive-based oleocanthal as a dual HER2-MET inhibitor for the control of breast cancer. Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 2018.
4. M. Mohyeldin, A. Siddique, A. Goda, B. Garetty and K El Sayed; Discovery of c-Met & EGFR marine natural product inhibitors for breast malignancies control. Innovations in Marine Natural Products Research: From Discovery to Application Gordon Research Conference, 2018.
5. M. Mohyeldin; Olive secoiridoid semisynthetic analogs as novel c-Met inhibitors. MALTO Medicinal Chemistry Podium Presentation, 2016.
6. M. Mohyeldin; Directed discovery of natural product-based scaffolds targeting the c-Met kinase using active-site specific virtual screening. American Association of Pharmaceutical Sciences (AAPS) Symposium Presentation, 2016.
7. S. Egbert, H. Elsayed, H. Ebrahim, M. Mohyeldin, J. Bhattacharjee, and K. El Sayed; Bioassay-guided discovery of the Louisiana-based lichen depsides as promising hits for controlling breast cancer through targeting HGF/c-Met axis. ULM Student Symposium, 2016.
8. M. Mohyeldin, M. Akl, J. Cardelli, and K. El Sayed; The oleocanthal-based homovanillyl sinapate as a novel dual c-Met-ABL1 inhibitor. ULM Student Symposium, 2016.
9. M. Mohyeldin, B. Busnena, M. Akl, and K. El Sayed; c-Met inhibitory olive secoiridoids and semisynthetic bioisosteres: In vitro and in vivo activities for the control of invasive breast cancer. ULM Student Symposium, 2014.
10. M. Mohyeldin and K. El Sayed; Optimization of standardized extra-virgin olive oil secoiridoid rich fraction as a new dietary-based c-Met inhibitor for the control of metastatic breast malignancies. MALTO Medicinal Chemistry Meeting, 2013.
• Active member in the NIH/NCI funded project entitled, “Design of novel c-Met inhibitors inspired by olive phenolics-1R15CA167475-01” (2013-2016).
• Active member in the Biomedical Research Foundation funded project entitled “Novel PCSK9-LDLR interaction natural product inhibitors for neurological disorders” (2018 – 2019).